Business Wire

ORAL-NICOTINE-COMMISSION

6.12.2022 08:03:40 CET | Business Wire | Press release

Share
Sweden Achieves the Lowest Smoking Rate in Europe and is on Track to Become Officially Smoke-Free - The EU Must Take Note

Swedish authorities officially confirmed that the current level of smoking in Sweden has fallen to 5,6%. This makes Swedes the only European nation close to reaching the smoke-free goal set by the EU 18 years ahead of the 2040 target.

In an event organised by the Oral Nicotine Commission in Stockholm, participants took stock of Sweden’s incredible achievements and leadership in the race to end smoking. It is about to become the first country in the world to be defined as “smoke free”, representing a share of less than 5% of the population smoking.

Sweden’s smoking rates have shot down since the 1980s from 35% down to below 6% - a feat that is yet to be replicated by any other nation in the world. The next lowest smoking rate in Europe is double that of Sweden’s, with the EU average sitting somewhere around 23%, four times higher than in Sweden. The result is the lowest tobacco mortality rate in Europe.

A group of leading public health professionals, consumer advocates and harm reduction experts that met to celebrate the achievement on 30 November 2022 in Stockholm have reaffirmed their call to policymakers around the world to ensure that less harmful alternatives to smoking are available to support smokers to quit.

Commenting at the event, Dr. Delon Human, President of Health Diplomats and organiser of the event in Stockholm said: “If all smokers in the world, some 1.1 billion people, would switch to one of less harmful alternative smoke-free, nicotine-based products, it could prevent disease and save millions of lives worldwide. Sweden has found the fire-escape for smokers. We need to work together to repeat the Swedish experience globally to save lives.”

This incredible success story gave attendees the chance to better understand Sweden’s recipe to success, key to which is its openness to less harmful alternatives to smoking. Snus has been at the forefront of the reduction measures, but in recent years, nicotine pouches and e-cigarettes have become another valuable tool for Swedish smokers aiming to quit.

The progressive, pro harm-reduction Swedish model is clearly distinct from the policies proposed by international organisations in favour of tobacco control. At an EU level, harm reduction advocates have fought hard to have harm reduction recognised in the European Beating Cancer Plan. The WHO still refuses to acknowledge its value, despite the fact that harm reduction is explicitly recognised in the Framework Convention for Tobacco Control.

Commenting at the event, Professor Karl Fagerström said: “The upcoming Swedish EU presidency is a great opportunity to share their 5% success story to other EU countries. We hope that Sweden will be generous with sharing this know-how internationally.”

Speakers at the conference emphasised the need for sound evidence-based policy interventions in tobacco control. This translates to the broad adoption of tobacco harm reduction policies that support a journey to quitting smoking.

Ensuring that less harmful alternatives to smoking are affordable, accessible and affordable will be paramount to ensure that other countries can replicate Sweden’s success. This event is the start of much needed discussion of this topic.

The Oral Nicotine Commission is a global not-for-profit association that helps build the evidence base and raise awareness of Oral Nicotine among both governments, public health leaders and the public, thus countering negative, unfounded preconceptions and stereotypes. It addresses policy, science, consumer issues and relevant product innovations. Its views are independent of any brand or manufacturer and focuses on the individual and population health needs of adult smokers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005671/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye